 SYDNEY, Sept. 13, 2019 PRNewswire -- Australian oncology-focused biotech company Kazia Therapeutics Ltd ASX: KZA, NASDAQ: KZIA is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation Growth Awards. The Awards celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand and were presented by New Zealand Prime Minister Jacinda Arden at a ceremony in Auckland on September 12. Kazia was recognised for being an innovative, product-focused and agile company and the award also reflected its significant progress in the clinical testing of its lead candidate, GDC-0084, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults, as well as other forms of brain cancer. 